The representative compound, PROTAC 12 (Table 3), potently degraded AR in AR + breast cancer cell lines and was much more potent than enzalutamide in inhibition of cell growth and induction of cell cycle arrest and/or apoptosis. This evidence concerns the gene AR and breast carcinoma.